Eli Lilly’s orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.
Related Posts
SoftBank raises $4.8 billion from T-Mobile share sale, term sheet shows: Reuters
Japan’s SoftBank raised $4.8 billion from a sale of 21.5 million T-Mobile shares at $224 each, according to a term sheet reviewed by Reuters.
European markets fall over 1% as trading begins after Fed signals fewer rate cuts ahead; BOE decision in focus
European markets fell sharply at the open Thursday, following their global counterparts lower.